Transaction · 0001493152-26-045713

Pershing Edward

Pershing Edward, CEO, reported a transaction classified as exercise at PROVECTUS BIOPHARMACEUTICALS, INC.. A 10b5-1 reference was not detected in the stored filing text.

exerciseSEC transaction code MCEO
PVCTPROVECTUS BIOPHARMACEUTICALS, INC.
Filing timeOct 05
Trade dateOct 03, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position tradedUnavailableNot calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

PVCT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
PVCT since 2026-10-05Filed today · pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
exercise
Code M
Identifier
0001493152-26-045713
8% Unsecured Convertible Promissory Note
Transaction date
Oct 03, 2026
Filed Oct 05, 2026, 02:52 PM · 2d delay
Shares
—
$0.00 per share
Estimated value
—
Computed from shares × price
Holdings after
—
Direct

Filing warnings

Notes recorded with this filing
1 warning
missing sharesThe filing did not provide usable transaction shares.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership
-14score
Filing-only score

-14

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO

Officer YesDirector Yes10% YesOther No
Footnotes & amended
  1. F1

    Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

  2. F2

    The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate…

  3. F3

    The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note…

  4. F4

    On October 03, 2026, the 2025 Note converted into 13,216 shares of Series D-1 Preferred Stock.

Original filing · 0001493152-26-045713
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

PVCT